Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial

American Heart Journal

Volumn 145, Issue 1, 2003, Pages 179-186

  Russell, Stuart D ^a   Selaru, Paulina ^b   Pyne, David A ^b   Ghazzi, Maha M ^b   Massey, Kenneth D ^b   Pressler, Milton ^b   Serikoff, Alexis ^c   Coats, Andrew J S ^d   Bonow, Robert O ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c ASTELLAS PHARMA INC   (Japan)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SCREENING; EXERCISE; EXERCISE TEST; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0037221858     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.39     Document Type: Article

References (36)

1. Narang R, Swedberg K, Cleland JG. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-34.
2. Lipicky RJ, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993;22(A Suppl):179-84A.
3. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(6 Suppl):VI-40-8.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
5. CIBIS Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
6. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
7. Eriksson H. Heart failure: A growing public health problem. J Intern Med 1995;237:135-41.
8. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
9. Burrell LM, Risvanis J, Johnston Cl, et al. Vasopressin receptor antagonism: A therapeutic option in heart failure and hypertension. Exp Physiol 2000;85S:259S-65S.
10. Szatalowicz VL, Arnold PE, Chaimovitz C, et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6.
11. Goldsmith SR, Francis GS, Levine TB, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1:1391-5.
12. Riegger GAJ, Liebau G, Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 1982;72:49-52.
13. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
14. 1 receptor. Mol Cell Biochem 1999;195:93-8.
15. Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;38:198-205.
16. Myers J, Froelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation 1990;82:1839-46.
17. Cohn JN, Rajfer SI, and attendees. Evaluation of functional capacity in heart failure: A consensus conference. Heart Fail 1990;6:169-73.
18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;3451:709-17.
19. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure: Content, reliability and validity of a new measure: The Minnesota Living with Heart Failure questionnaire. Heart Fail 1987;3:198-209.
20. Wilson JR. Exercise and the failing heart. Cardiol Clin 1987;5:171-81.
21. Russell SD, McNeer FR, Beere PA, et al. Improvement in the mechanical efficiency of walking: An explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Am Heart J 1998;135:107-14.
22. Ziesche S, Cobb FR, Cohn JN, et al. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure: Results from V-HeFT I and V-HeFT II. Circulation 1993;87(6 Suppl):VI-56-64.
23. Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: A rest and exercise hemodynamic study. Circulation 1983;67:807-16.
24. Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol 1985;5:101-7.
25. Hermansen L, Saltin B. Oxygen uptake during maximal treadmill and bicycle exercise. J Appl Physiol 1969;26:31-7.
26. Page E, Cohen-Solal A, Jondeau G, et al. Comparison of treadmill and bicycle exercise in patients with chronic heart failure. Chest 1994;106:1002-6.
27. Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993;22:65-72.
28. Weber KT, Kinasewitz GT, Janicki JS, et al. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation 1982;65:1213-23.
29. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
30. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation 1989;79:324-9.
31. Elborn JS, Riley M, Stanford CF, et al. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure. Br J Clin Pharmacol 1990;29:519-24.
32. Simonton CA, Higginbotham MB, Cobb FR. The ventilatory threshold: Quantitative analysis of reproducibility and relation to arterial lactate concentration in normal subjects and in patients with chronic congestive heart failure. Am J Cardiol 1988;62:100-7.
33. Lipkin DP, Perrins J, Poole-Wilson PA. Respiratory gas exchange in the assessment of patients with impaired ventrlcular function. Br Heart J 1985;54:321-8.
34. Wolfel EE, Boland D, Adair O, et al. Fixed submaximal workload test: Superiority over maximal exercise testing in evaluating responses to medical therapy in chronic heart failure [abstract]. Circulation 1997;96(1 Suppl):1-83.
35. Chomsky DB, Lang CC, Rayos G, et al. Treatment of subclinical fluid retention in patients with symptomatic heart failure: Effect on exercise performance. J Heart Lung Transplant 1997;16:846-53.
36. 2. Eur Heart J 2000;21:154-61.